UNSPSC 51151653: Prifinium

This classification denotes an anticholinergic agent with the molecular structure C22H28N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 3C7TTK1K7K chemically known as 3-(diphenylmethylene)-1,1-diethyl-2-methylpyrrolidinium but generally known as prifinium, which bears US NIH Compound Identifier 4905. European Medicines Agency schedules Prifinium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04037MIG. As of Q4 2014, PRIFINIUM remains the US FDA Preferred Term for this commodity.

Prifinium bears US NLM identifiers UMLS ID C0771424 and NCI Concept Code C84105. SMILES: [N]1(C(/C(=C(/C2CCCCC2)C2CCCCC2)CC1)C)(CC)CC.

UNSPSC 51151653 Prifinium is a Commodity code under which state and local governments procure pharmaceutical products, including naloxone (an opioid overdose reversal medication) and related drug management systems. The recent solicitations show health departments and state health agencies buying finished pharmaceutical inventory for community health programs and exploring direct-to-manufacturer pharmacy benefit arrangements to manage prescription costs and fulfillment. Issuing bodies span county health departments and state health and human services commissions, each managing supply chains for naloxone distribution networks and pharmacy benefit administration at the population level.

Seminole County, Florida posted an IFB on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the response deadline was July 26, 2023. The Texas Health and Human Services Commission issued an RFI on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and group purchasing organization channels, targeting negotiated net pricing models for self-insured employee health plans. Recent activity is concentrated in Florida and Texas, with the code showing movement toward both direct pharmaceutical procurement (county-level naloxone acquisition) and state-level exploration of alternative distribution and contracting models to reduce pharmacy benefit costs.